FK506-binding protein 12 and Calcineurin (FKBP12 and CaN)

FKBP12 (FK506-binding protein 12) is a small cytosolic immunophilin with peptidyl-prolyl cis-trans isomerase activity, functioning as a chaperone and regulator of several intracellular processes, including calcium channel activity and TGF-β signaling. Calcineurin (protein phosphatase 2B) is a ubiquitously expressed, calcium/calmodulin-dependent serine/threonine protein phosphatase essential for T-cell activation and many other critical functions, including vesicle trafficking and immune regulation. Clinically, immunosuppressive drugs such as tacrolimus exploit the physical interaction between FKBP12 and calcineurin; FKBP12 binds tacrolimus to form a complex that then specifically and potently inhibits calcineurin, blocking T-cell activation and preventing organ rejection. Targeting this pathway has become fundamental in immunosuppressive therapy, but also presents significant safety challenges due to the broad physiological importance of both FKBP12 and calcineurin[1][2][4][7][9].

Other names

FKBP12FK506-binding protein 12FKBP-1212-kDa FK506-binding proteinPPIase FKBP1AFKBP1ACalcineurinProtein phosphatase 2BCaNPPP3CAprotein phosphatase 3 catalytic subunit alpha isoform

Tacrolimus binds FKBP12; the FKBP12-tacrolimus complex inhibits calcineurin’s phosphatase activity, preventing dephosphorylation and nuclear translocation of NFAT, leading to immunosuppression. Cyclosporin A binds to cyclophilin; the complex similarly inhibits calcineurin. Disruption of FKBP12-calcineurin interaction affects vesicle trafficking proteins, with roles in neuroprotection. Rapamycin binds FKBP12 to inhibit mTOR but does not inhibit calcineurin.